相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Late Toxicity and Long-Term Local Control in Patients With Ultra- Central Lung Tumours Treated by Intensity-Modulated Radiotherapy- Based Stereotactic Ablative Body Radiotherapy With Homogenous Dose Prescription
A. M. Mihai et al.
CLINICAL ONCOLOGY (2021)
Ablative radiotherapy for ultracentral lung cancers: Dosimetric, geometric, and volumetric predictors of outcomes and toxicity
William G. Breen et al.
RADIOTHERAPY AND ONCOLOGY (2021)
The HILUS-Trial-a Prospective Nordic Multicenter Phase 2 Study of Ultracentral Lung Tumors Treated With Stereotactic Body Radiotherapy
Karin Lindberg et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Ultra-central lung tumors: safety and efficacy of protracted stereotactic body radiotherapy
Joyce E. Lodeweges et al.
ACTA ONCOLOGICA (2021)
Stereotactic ablative radiotherapy for the comprehensive treatment of 1-3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial
Robert Olson et al.
BMC CANCER (2020)
Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial
Andrea Bezjak et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
David A. Palma et al.
LANCET (2019)
Analysis of Toxic Effects With Antiangiogenic Agents Plus Stereotactic Body Radiation in Ultracentral Lung Tumors
Chunyu Wang et al.
JAMA ONCOLOGY (2019)
Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial
David A. Palma et al.
BMC CANCER (2019)
SUNSET: Stereotactic Radiation for Ultracentral Non-Small-Cell Lung Cancer-A Safety and Efficacy Trial
Meredith Giuliani et al.
CLINICAL LUNG CANCER (2018)
Normal Tissue Complication Probability Modeling of Pulmonary Toxicity After Stereotactic and Hypofractionated Radiation Therapy for Central Lung Tumors
H. Tekatli et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2018)
Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5
Robert Olson et al.
BMC CANCER (2018)
Canadian Phase III Randomized Trial of Stereotactic Body Radiotherapy Versus Conventionally Hypofractionated Radiotherapy for Stage I, Medically Inoperable Non-Small-Cell Lung Cancer - Rationale and Protocol Design for the Ontario Clinical Oncology Group (OCOG)-LUSTRE Trial
Anand Swaminath et al.
CLINICAL LUNG CANCER (2017)
Precision Hypofractionated Radiation Therapy in Poor Performing Patients With Non-Small Cell Lung Cancer: Phase 1 Dose Escalation Trial
Kenneth D. Westover et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2015)
Stereotactic Ablative Radiation Therapy for Centrally Located Early Stage or Isolated Parenchymal Recurrences of Non-Small Cell Lung Cancer: How to Fly in a No Fly Zone
Joe Y. Chang et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2014)
Dose-Limiting Toxicity After Hypofractionated Dose-Escalated Radiotherapy in Non-Small-Cell Lung Cancer
Donald M. Cannon et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
The North American experience with stereotactic body radiation therapy in non-small cell lung cancer
Robert D. Timmerman et al.
JOURNAL OF THORACIC ONCOLOGY (2007)
Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer
Robert Timmerman et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Bronchial stenosis: An underreported complication of high-dose external beam radiotherapy for lung cancer?
KL Miller et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2005)
分享论文
